U.S. Hormone Replacement Therapy Market Size, Share & Trends Analysis Report By Product, By Route Of Administration, By Disease Type (Menopause, Hypothyroidism, Male Hypogonadism), And Segment Forecasts, 2020 - 2027

Table of Contents

Chapter 1 Methodology
                   1.1 Market segmentation
                       1.1.1 Estimates and Forecast Timeline
                   1.2 Research Methodology
                   1.3 Information procurement
                       1.3.1 Purchased Database
                       1.3.2 GVR’s Internal Database
                       1.3.3 Secondary Sources
                       1.3.4 Primary Research
                       1.3.5 Details of Primary Research
                   1.4 Information or Data Analysis
                       1.4.1 Data Analysis Models
                   1.5 Market Formulation & Validation
                   1.6 Model Details
                       1.6.1 Commodity Flow Analysis
                           1.6.1.1 Approach 1: Commodity Flow Approach
                           1.6.1.2 Approach 2: Country-wise market estimation using the bottom-up approach
                   1.7 U.S. Market: CAGR Calculation
                   1.8 Research Assumptions
                   1.9 List of Secondary Sources
                   1.10 List of Primary Sources
                   1.11 Objectives
                       1.11.1 Objective 1
                       1.11.2 Objective 2
                   1.12 List of Abbreviations
Chapter 2 Executive Summary
                   2.1 Market Snapshot
Chapter 3 Industry Outlook
                   3.1 Market Segmentation
                   3.2 Penetration & Growth Prospect Mapping
                   3.3 Regulatory and Reimbursement Framework
                   3.4 Market Variable Analysis
                       3.4.1 Market driver analysis
                           3.4.1.1 Increase in the number of patients undergoing Hormone Replacement Therapy
                           3.4.1.2 Rising prevalence of hormonal disorders
                           3.4.1.3 Technological developments in drug delivery systems
                       3.4.2 Market restraint analysis
                           3.4.2.1 High cost of treatment
                           3.4.2.2 Risk of side effects
                   3.5 Industry Analysis Tools
                       3.5.1 PESTEL Analysis
                       3.5.2 Porter’s five forces analysis
                   3.6 Major Deals and Strategic Alliances Analysis
                       3.6.1 New Product Launch
                       3.6.2 Mergers and Acquisitions
                       3.6.3 Promotional Agreements & Joint Ventures
                       3.6.4 Conferences and Campaigns
                   3.7 Pipeline Analysis
Chapter 4 U.S. Hormone Replacement Therapy Market: Product Segment Analysis
                   4.1 U.S. HRT Market: Product Movement Analysis
                   4.2 Estrogen & Progesterone Replacement Therapy
                       4.2.1 Estrogen & Progesterone replacement therapy market, 2016 - 2027 (USD Million)
                   4.3 Human Growth Hormone (HGH) Replacement Therapy
                       4.3.1 HGH replacement therapy market, 2016 - 2027 (USD Million)
                   4.4 Thyroid Hormone Replacement Therapy
                       4.4.1 Thyroid hormone replacement therapy market, 2016 - 2027 (USD Million)
                   4.5 Testosterone Replacement Therapy
                       4.5.1 Testosterone replacement therapy market, 2016 - 2027 (USD Million)
                   4.6 Parathyroid Hormone
                       4.6.1 Parathyroid Hormone market, 2016 - 2027 (USD Million)
Chapter 5 U.S. Hormone Replacement Therapy: Route of Administration Segment Analysis
                   5.1 U.S. HRT Market: Route of Administration Movement Analysis
                   5.2 Oral
                       5.2.1 Oral market, 2016 - 2027 (USD Million)
                   5.3 Parenteral
                       5.3.1 Parenteral market, 2016 - 2027 (USD Million)
                   5.4 Transdermal
                       5.4.1 Transdermal market, 2016 - 2027 (USD Million)
                   5.5 Others
                       5.5.1 Others market, 2016 - 2027 (USD Million)
Chapter 6 U.S. Hormone Replacement Therapy Market: Disease Type Segment Analysis
                   6.1 U.S. HRT Market: Disease Type Movement Analysis
                   6.2 Menopause
                       6.2.1 Menopause market, 2016 - 2027 (USD Million)
                   6.3 Hypothyroidism
                       6.3.1 Hypothyroidism market, 2016 - 2027 (USD Million)
                   6.4 Male Hypogonadism
                       6.4.1 Male Hypogonadism market, 2016 - 2027 (USD Million)
                   6.5 Growth Hormone Deficiency
                       6.5.1 Growth Hormone Deficiency market, 2016 - 2027 (USD Million)
                   6.6 Hypoparathyroidism
                       6.6.1 Hypoparathyroidism, 2016 - 2027 (USD Million)
Chapter 7 Hormone Replacement Therapy Market - Competitive Analysis
                   7.1 Company Categorization
                       7.1.1 Market Differentiators
                       7.1.2 Innovators
                       7.1.3 Market Leaders
                   7.2 Vendor Landscape
                       7.2.1 List of key distributors and channel partners
                       7.2.2 Key customers
                   7.3 Heat map analysis
                   7.4 Public Companies
                       7.4.1 Key company analysis, 2019
                       7.4.2 Company market position analysis
                   7.5 Company Profiles
                       7.5.1 Bayer AG
                           7.5.1.1 Company Overview
                           7.5.1.2 Financial Performance
                           7.5.1.3 Product Benchmarking
                           7.5.1.4 Strategic Initiatives
                       7.5.2 Pfizer, Inc.
                           7.5.2.1 Company Overview
                           7.5.2.2 Financial Performance
                           7.5.2.3 Product Benchmarking
                           7.5.2.4 Strategic Initiatives
                       7.5.3 Merck & Co., Inc.
                           7.5.3.1 Company Overview
                           7.5.3.2 Financial Performance
                           7.5.3.3 Product Benchmarking
                           7.5.3.4 Strategic Initiatives
                       7.5.4 Abbott
                           7.5.4.1 Company Overview
                           7.5.4.2 Financial Performance
                           7.5.4.3 Product Benchmarking
                           7.5.4.4 Strategic Initiatives
                       7.5.5 Mylan N.V.
                           7.5.5.1 Company Overview
                           7.5.5.2 Financial Performance
                           7.5.5.3 Product Benchmarking
                           7.5.5.4 Strategic Initiatives
                       7.5.6 Novo Nordisk A/S
                           7.5.6.1 Company Overview
                           7.5.6.2 Financial Performance
                           7.5.6.3 Product Pipeline
                           7.5.6.4 Strategic Initiatives
                       7.5.7 Eli Lilly and Company
                           7.5.7.1 Company Overview
                           7.5.7.2 Financial Performance
                           7.5.7.3 Product Benchmarking
                           7.5.7.4 Strategic Initiatives
                       7.5.8 F. Hoffmann-La Roche Ltd. (Genentech)
                           7.5.8.1 Company Overview
                           7.5.8.2 Financial Performance
                           7.5.8.3 Product Benchmarking
                       7.5.9 Noven Pharmaceuticals, Inc. (Hisamitsu Pharmaceutical Co., Inc.)
                           7.5.9.1 Company Overview
                           7.5.9.2 Financial Performance
                           7.5.9.3 Product Benchmarking
                           7.5.9.4 Strategic Initiatives
                       7.5.10 ASCEND Therapeutics US, LLC. (Besins Healthcare)
                           7.5.10.1 Company Overview
                           7.5.10.2 Product Benchmarking
                           7.5.10.3 Strategic Initiatives
                       7.5.11 AbbVie Inc.
                           7.5.11.1 Company Overview
                           7.5.11.2 Financial Performance
                           7.5.11.3 Product Benchmarking
                           7.5.11.4 Strategic Initiatives

List of Tables

TABLE 1 List of secondary sources
TABLE 2 List of Abbreviation
TABLE 3 Regulatory framework
TABLE 4 Eligibility table for menopause treatment services
TABLE 5 Eligibility table for hormone replacement therapy
TABLE 6 Leading market players are anticipated to witness the highest growth
TABLE 7 List of key distributors and Compounding Pharmacies
TABLE 8 Key Company Analysis
TABLE 9 U.S. Hormone Replacement Therapy Market, By product, 2016 - 2027 (USD Million)
TABLE 10 U.S. Hormone Replacement Therapy Market, By route of administration, 2016 - 2027 (USD Million)
TABLE 11 U.S. Hormone Replacement Therapy Market, By disease type, 2016 - 2027 (USD Million)

List of Figures

Fig. 1 U.S. Hormone Replacement Therapy Market Segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary Research Pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market summary
Fig. 10 U.S. HRT Market Segmentation
Fig. 11 Penetration & Growth Prospect Mapping
Fig. 12 Market Driver Impact Analysis (Current & future impact)
Fig. 13 Market Restraint Impact Analysis (Current & future impact)
Fig. 14 PESTEL Analysis
Fig. 15 Porter’s Five Forces Analysis
Fig. 16 U.S. HRT market product outlook: Key takeaways
Fig. 17 U.S. HRT Market: Product Movement Analysis
Fig. 18 Estrogen & Progesterone Replacement Therapy Market, 2016 - 2027 (USD Million)
Fig. 19 HGH Replacement Therapy Market, 2016 - 2027 (USD Million)
Fig. 20 Thyroid Hormone Replacement Therapy Market, 2016 - 2027 (USD Million)
Fig. 21 Testosterone Replacement Therapy Market, 2016 - 2027 (USD Million)
Fig. 22 Parathyroid Hormone Market, 2016 - 2027 (USD Million)
Fig. 23 U.S. HRT Market Route of Administration Outlook: Key takeaways
Fig. 24 U.S. HRT Market: Route of Administration Movement Analysis
Fig. 25 Oral Market, 2016 - 2027 (USD Million)
Fig. 26 Parenteral Market, 2016 - 2027 (USD Million)
Fig. 27 Transdermal Market, 2016 - 2027 (USD Million)
Fig. 28 Others Market, 2016 - 2027 (USD Million)
Fig. 29 U.S. HRT Market Disease Type Outlook: Key takeaways
Fig. 30 U.S. HRT Market: Disease Type Movement Analysis
Fig. 31 Menopause Market, 2016 - 2027 (USD Million)
Fig. 32 Hypothyroidism Market, 2016 - 2027 (USD Million)
Fig. 33 Male Hypogonadism Market, 2016 - 2027 (USD Million)
Fig. 34 Growth Hormone Deficiency Market, 2016 - 2027 (USD Million)
Fig. 35 Hypoparathyroidism, 2016 - 2027 (USD Million)
Fig. 36 Market differentiators
Fig. 37 Heat map analysis